ProQR Therapeutics BV (PRQR) has released an update.
ProQR Therapeutics NV shared promising preclinical proof of concept data for AX-0810, their Axiomer™ RNA Editing Program for treating cholestatic diseases, which showed target engagement and biomarker changes in non-human primates. The technology, presented at the ASGCT Annual Meeting, is expected to enter clinical trials by late 2024 or early 2025. ProQR’s innovative Axiomer™ platform potentially offers a new class of RNA-based medicines for a variety of diseases.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.
